Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KARS1 | Q15046 | 4/20 | 0.43 |
| ▸ | VCP | P55072 | 1/20 | 0.35 |
| ▸ | PIM2 | Q9P1W9 | 2/20 | 0.34 |
| ▸ | FAAH | O00519 | 2/20 | 0.34 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | CLK2 | P49760 | 3/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.33 |
| ▸ | PRKCI | P41743 | 1/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16776072 | 0.92 | VCP (0.42) | KARS1VCPPIM2FAAHSIRT2 | |
| SCHEMBL16776071 | 0.89 | VCP (0.39) | KARS1VCPCLK2LRRK2 | |
| SCHEMBL16776005 | 0.87 | KARS1 (0.50) | KARS1FAAHSIRT2ABL1PRKCI | |
| SCHEMBL16776079 | 0.86 | SLC5A1 (0.37) | KARS1VCPPIM2ABL1CLK2 | |
| SCHEMBL16776090 | 0.86 | FGFR4 (0.40) | KARS1VCPFAAHCLK2LRRK2 | |
| SCHEMBL16775818 | 0.83 | ALOX15 (0.46) | KARS1FAAHSIRT2CLK2PIM1 | |
| SCHEMBL16776027 | 0.83 | KARS1 (0.44) | KARS1FAAHSIRT2ABL1PRKCI | |
| SCHEMBL16775959 | 0.82 | ABL1 (0.43) | FAAHSIRT2ABL1PDE10ACYP3A4 | |
| SCHEMBL16776110 | 0.82 | KARS1 (0.39) | KARS1FAAHMAP3K12 | |
| SCHEMBL17618567 | 0.81 | KARS1 (0.41) | KARS1VCPPIM2FAAHSIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | KARS1 1760/4885VCP 1270/4885PIM2 3242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.